CBFB and acute myeloid leukemia: When comparing CHEK2-path AML patient cytogenetics with the distribution observed in unselected, de novo AML patients from the TCGA AML dataset, core binding factor (CBF) rearrangements [CBFB-MYH11 or RUNX1-RUNX1T1] were more common in patients with CHEK2-path variants (25%, 4/12) versus TCGA de novo AML (10%, 19/200; P = 0.029, Fisher’s exact; Supplemental Fig. 1A).